期刊
MINI-REVIEWS IN MEDICINAL CHEMISTRY
卷 11, 期 12, 页码 1019-1030出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138955711797247725
关键词
Antitumor; covalent inhibition; cysteine-trap; EGFR; erbB receptors; irreversible inhibitors; NSCLC
Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes. They contain a cysteine-reactive portion forming a covalent bond with the protein. Irreversible kinase inhibitors have been advanced to clinical studies, mostly characterized by an acrylamide or butynamide warhead. However, the clinical usefulness of these compounds has been hampered by resistances, toxicity and pharmacokinetic problems. Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compounds with improved selectivity and pharmacokinetic properties. This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据